Madrigal Pharmaceuticals, Inc.
DE ˙ DB ˙ US5588681057
426,20 € ↑6,40 (1,52%)
2026-06-04
DEL PRIS
SecurityDE:YDO1 / Madrigal Pharmaceuticals, Inc.
InstitutionPrincipal Financial Group Inc
Latest Disclosed Ownership1,239 shares
Latest Disclosed Value $ 648,579
Principal Financial Group Inc reports 82.94% decrease in ownership of YDO1 / Madrigal Pharmaceuticals, Inc.

On May 4, 2026 - Principal Financial Group Inc filed a 13F-HR form disclosing ownership of 1,239 shares of Madrigal Pharmaceuticals, Inc. (DE:YDO1) valued at $557,922 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 2, 2026 disclosing 7,261 shares of Madrigal Pharmaceuticals, Inc.. This represents a change in shares of -82.94% during the quarter. The current value of the position is $528,062 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-04 2026-03-31 13F MADRIGAL PHARMACEUTICALS COM 558868105 1,239 -6,022 -82.94 649 -84.67 0.0003
2026-02-02 2025-12-31 13F MADRIGAL PHARMACEUTICALS COM 558868105 7,261 -4,807 -39.83 4,228 -23.61 0.0022
2025-11-04 2025-09-30 13F MADRIGAL PHARMACEUTICALS COM 558868105 12,068 2,862 31.09 5,535 98.67 0.0028
2025-08-08 2025-06-30 13F MADRIGAL PHARMACEUTICALS COM 558868105 9,206 7,772 541.98 2,786 487.76 0.0015
2025-04-28 2025-03-31 13F MADRIGAL PHARMACEUTICALS COM 558868105 1,434 -96 -6.27 475 0.42 0.0003
2025-01-31 2024-12-31 13F MADRIGAL PHARMACEUTICALS COM 558868105 1,530 -96 -5.90 472 36.81 0.0003
2024-10-31 2024-09-30 13F MADRIGAL PHARMACEUTICALS COM 558868105 1,626 -1,430 -46.79 345 -59.70 0.0002
2024-07-29 2024-06-30 13F MADRIGAL PHARMACEUTICALS COM 558868105 3,056 -946 -23.64 856 -19.85 0.0005
2024-04-29 2024-03-31 13F MADRIGAL PHARMACEUTICALS COM 558868105 4,002 127 3.28 1,069 19.20 0.0006
2024-02-07 2023-12-31 13F MADRIGAL PHARMACEUTICALS COM 558868105 3,875 142 3.80 897 64.40 0.0006
2023-11-02 2023-09-30 13F MADRIGAL PHARMACEUTICALS COM 558868105 3,733 -78 -2.05 545 -38.07 0.0004
2023-08-07 2023-06-30 13F MADRIGAL PHARMACEUTICALS COM 558868105 3,811 -119 -3.03 880 -7.56 0.0006
2023-05-09 2023-03-31 13F MADRIGAL PHARMACEUTICALS COM 558868105 3,930 -267 -6.36 952 -21.84 0.0007
2023-02-09 2022-12-31 13F MADRIGAL PHARMACEUTICALS COM 558868105 4,197 366 9.55 1,218 389.16 0.0009
2022-11-09 2022-09-30 13F MADRIGAL PHARMACEUTICALS COM 558868105 3,831 -65 -1.67 249 -10.75 0.0002
2022-08-10 2022-06-30 13F MADRIGAL PHARMACEUTICALS COM 558868105 3,896 1,758 82.23 279 32.86 0.0002
2022-05-09 2022-03-31 13F MADRIGAL PHARMACEUTICALS COM 558868105 2,138 2,138 210 0.0001
2022-02-09 2021-12-31 13F MADRIGAL PHARMACEUTICALS COM 558868105 0 -3,184 -100.00 0 -100.00
2021-11-09 2021-09-30 13F MADRIGAL PHARMACEUTICALS COM 558868105 3,184 -515 -13.92 254 -29.44 0.0002
2021-08-10 2021-06-30 13F MADRIGAL PHARMACEUTICALS COM 558868105 3,699 -1,647 -30.81 360 -42.40 0.0002
2021-05-10 2021-03-31 13F MADRIGAL PHARMACEUTICALS COM 558868105 5,346 -61 -1.13 625 3.99 0.0004
2021-02-23 2020-12-31 13F/A-1 MADRIGAL PHARMACEUTICALS COM 558868105 5,407 2,181 67.61 601 56.92 0.0004
2021-02-08 2020-12-31 13F MADRIGAL PHARMACEUTICALS COM 558868105 5,407 2,181 601 236.4427
2020-11-06 2020-09-30 13F MADRIGAL PHARMACEUTICALS COM 558868105 3,226 -156 -4.61 383 0.00 0.0003
2020-08-05 2020-06-30 13F MADRIGAL PHARMACEUTICALS COM 558868105 3,382 3,382 383 0.0003
2020-05-12 2020-03-31 13F MADRIGAL PHARMACEUTICALS COM 558868105 0 -2,320 -100.00 0 -100.00
2020-02-05 2019-12-31 13F MADRIGAL PHARMACEUTICALS COM 558868105 2,320 2,320 211 0.0002
2019-11-13 2019-09-30 13F MADRIGAL PHARMACEUTICALS COM 558868105 0 -2,254 -100.00 0 -100.00
2019-08-12 2019-06-30 13F MADRIGAL PHARMACEUTICALS COM 558868105 2,254 35 1.58 236 -15.11 0.0002
2019-05-10 2019-03-31 13F MADRIGAL PHARMACEUTICALS COM 558868105 2,219 177 8.67 278 20.87 0.0003
2019-02-14 2018-12-31 13F MADRIGAL PHARMACEUTICALS COM 558868105 2,042 -7,263 -78.05 230 -88.46 0.0002
2018-11-14 2018-09-30 13F MADRIGAL PHARMACEUTICALS COM 558868105 9,305 556 6.36 1,993 -18.55 0.0018
2018-08-13 2018-06-30 13F MADRIGAL PHARMACEUTICALS COM 558868105 8,749 8,749 2,447 0.0022
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.